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Abstract: Purpose: Alphafetoprotein (AFP) is considered to be an
indicator of tumour activity in hepatocellular carcinoma (HCC). We
present a novel correlation of AFP response to radiologic response,
time-to-progression (TTP), progression-free survival (PFS), and over-
all survival (OS) in patients treated with locoregional therapies.
Patients and methods: Four hundred sixty-three patients with HCC
were treated with chemoembolization or radioembolization at our
institution. One hundred twenty-ﬁve patients with baseline AFP
higher than 200 ng/mL were studied for this analysis. AFP response
was deﬁned as more than 50% decrease from baseline. One hundred
nineteen patients with follow-up imaging were studied for the AFP
imaging correlation analysis. AFP response was correlated to radiologic
response, TTP, PFS, and OS. Multivariate analyses were performed.
Results: Eighty-one patients (65%) showed AFP response. AFP
response was seen in 26 (55%) of 47 and 55 (70%) of 78 of patients
treated with chemoembolization and radioembolization, respectively
(P = .12). WHO response was seen in 41 (53%) of 77 and 10 (24%) of
42 of AFP responders and nonresponders, respectively (P = .002). The
hazard ratio (HR) for TTP in AFP nonresponders compared with
responders was 2.8 (95% CI, 1.5–5.1). The HR for PFS was 4.2 (95%
CI, 2.4–7.2) in AFP nonresponders compared with responders. The
HR for OS in AFP nonresponders compared with responders was
5.5 (95% CI, 3.1–9.9) and 2.7 (95% CI, 1.6– 4.6) on univariate and
multivariate analyses, respectively.
Conclusion: The data presented support the use of AFP response seen
after locoregional therapy as an ancillary method of assessing
tumour response and survival, as well as an early objective screening
tool for progression by imaging.
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E-mail address: morris.sherman@uhn.on.ca.informative for the clinician managing patients at risk for or suf-
fering from hepatocellular carcinoma (HCC) under several differ-
ent circumstances. These include risk stratiﬁcation, surveillance,
prognosis, and monitoring of response to therapy. However, stud-
ies have suggested that for most of these circumstances the value
of measuring AFP is limited.
AFP testing might be used for hepatocellular carcinoma risk
stratiﬁcation, because the risk of future HCC is higher in those
with chronically elevated AFP than those with persistently nor-
mal AFP [1,2]. Although chronically elevated AFP indicates an
increased risk of developing HCC, this is usually in patients
already known to be at risk for HCC, and who are likely already
under surveillance for other reasons, such as the presence of cir-
rhosis or chronic hepatitis B. Thus, measuring AFP does not help
determine who should or should not undergo surveillance and is
therefore not really useful for risk stratiﬁcation.
Historically, AFP was used as a diagnostic test to conﬁrm the
presence of HCC in a patient presenting with liver failure and/
or a mass in the liver. This was before the availability of ultra-
sound or computerized tomography when a diagnosis of HCC
could only be made by angiography or by percutaneous biopsy
of an obvious liver mass. However, with the advent of ultrasonog-
raphy, computerized tomography, and magnetic resonance imag-
ing the importance of AFP as a diagnostic test has declined.
Very high AFP concentrations in serum are diagnostic of HCC
(in the absence of a testicular tumour), but anywhere between
20% and 80% of patients with HCC do not have elevated AFP,
depending on tumour size at diagnosis [3–5]. However, since
radiology is so highly speciﬁc, and is always required to conﬁrm
the diagnosis of HCC and to plan therapy, AFP testing seems
superﬂuous. Patients in whomHCC is not initially suspected, such
as those presenting with non-speciﬁc abdominal complaints, are
likely to have imaging such as an ultrasound, which will identify
if a mass is present. This would need to be conﬁrmed as HCC by
additional radiology. An occasional patient will have a diffusely
inﬁltrating HCC that is not detectable by imaging and under those
circumstances the AFP value might help conﬁrm the diagnosis.
In patients diagnosed with HCC an elevated AFP is an adverse
prognostic sign [6,7]. However, this is sufﬁciently variable that it
is of little clinical use. This test has not been used to exclude
patients from any particular form of therapy that might be indi-
cated for their lesion. For example, even though an elevated AFP
indicates a higher risk for HCC recurrence post liver transplant [8]
it is not used to exclude patients from receiving a new liver.
In 2001, I wrote an ‘‘obituary” for the use of alphafetoprotein
(AFP) as a surveillance test for hepatocellular carcinoma (HCC)10 vol. 52 j 939–940
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[9]. Nonetheless, AFP measurement remains in common use for
surveillance in patients at risk for HCC, despite ample evidence
that it is not a good surveillance test [10–12]. AFP measurement
clearly has not died as a surveillance test, although hopefully it
is in its death throes. However, measurement of AFP seems to have
been resurrected as a component of post-treatment follow-up.
AFP has long been used to monitor the response to HCC ther-
apy, a fall in AFP concentration being thought to indicate a good
response to treatment. However, this has seldom been correlated
with outcomes such as survival or any of the other commonly
used endpoints in oncology, such as time-to-progression or pro-
gression-free survival.
Recently there have been three studies that have correlated a
decline in AFP concentration after treatment with such endpoints.
Chan et al. [13] evaluated AFP response in patients undergoing
systemic chemotherapy. Riaz et al. [14] correlated AFP response
with tumour response by WHO and EASL criteria, as well as with
overall survival, time-to-progression, and progression-free sur-
vival in patients undergoing treatment with either chemoemboli-
zation or radioembolization. Finally, Chen et al. [15] evaluated AFP
response in patients undergoing treatment with thalidomide.
All three studies showed some degree of correlation between
the decline in AFP concentration after treatment and outcomes.
This led the authors in all three studies to recommend that AFP
monitoring should be included as part of clinical trials of HCC
therapy, particularly since treatment with molecular-targeted
agents might show survival advantage without showing major
changes in tumour size. Riaz et al. [14] make the point that it is
standard to perform radiology 3 months after treatment and at
three monthly intervals thereafter, while an AFP can be measured
easily and more frequently, and might predict response to treat-
ment sooner than radiology. Perhaps this is so, but radiology
remains the gold standard to assess response, and at least in their
paper, the AFP response was sufﬁciently heterogeneous that it
cannot be used to replace radiological assessment of response.
Of course, in HCC it is uncertain whether even radiological
response correlates well with survival. Only a few studies have
evaluated this. Given the severity of underlying liver disease in
many patients, death from liver failure is a confounding factor
in assessing outcome that has nothing to do with tumour
response. Riaz et al. [14] did not compare AFP as a predictor of
outcome vs. radiological response. Only if AFP is a better predic-
tor of outcome than radiology will it be a useful test.
Riaz et al. [14] also comment that the converse of their ﬁndings
also needs further study, namely whether increasing AFP post-
treatment correlates with a worse outcome. However, even if this
were true measuring AFP would once again only be useful if the
correlation between AFP and poor prognosis was better than the
correlation between radiological progression and poor prognosis.
AFP concentration in serum is a function of tumour burden.
The decline in AFP concentration seen after therapy is likely a
reﬂection of decline in tumour burden, and the improvement in
outcome also likely related to a decline in tumour burden. How-
ever, shrinkage of the tumour might not be a good indicator of
outcome with new agents that inhibit tumour metabolic path-
ways, such as sorafenib. In the registration studies for this agent
the response rate, in terms of tumour shrinkage was only about
3%, but nonetheless, survival was enhanced [16,17]. There is as
yet no information on how AFP behaves under these circum-
stances. It may be that there is little correlation between AFP
and outcome, particularly since the tumour burden does not
seem to change greatly.940 Journal of Hepatology 201AFP measurement has been around for a long time, but in
modern times has not found a niche that everyone agrees is use-
ful. It may be that it will be a useful measure of treatment efﬁ-
cacy, but I am not holding my breath. I suspect that the results
will be too heterogeneous to be useful. At present I remain
unconvinced that it contributes much to the management of
patients at risk for or with HCC.
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